- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Patent holdings for IPC class A61K 31/53
Total number of patents in this class: 4031
10-year publication summary
|
237
|
203
|
227
|
273
|
288
|
311
|
306
|
323
|
328
|
219
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4748 |
103 |
| Shionogi & Co., Ltd. | 885 |
80 |
| Janssen Pharmaceutica N.V. | 3161 |
54 |
| Gilead Sciences, Inc. | 2231 |
54 |
| Novartis AG | 10178 |
45 |
| Servier Pharmaceuticals, LLC | 134 |
44 |
| Incyte Corporation | 1066 |
38 |
| Hoffmann-La Roche Inc. | 3815 |
37 |
| The Regents of the University of California | 20802 |
37 |
| F. Hoffmann-La Roche AG | 7815 |
34 |
| Takeda Pharmaceutical Company Limited | 2712 |
34 |
| Taisho Pharmaceutical Co., Ltd. | 850 |
33 |
| Blueprint Medicines Corporation | 256 |
32 |
| Madrigal Pharmaceuticals, Inc. | 86 |
30 |
| AstraZeneca AB | 2824 |
25 |
| Genentech, Inc. | 4115 |
24 |
| Incyte Holdings Corporation | 625 |
24 |
| Skyhawk Therapeutics, Inc. | 150 |
24 |
| Bayer Pharma AG | 1010 |
23 |
| Eisai R&D Management Co., Ltd. | 1169 |
23 |
| Other owners | 3233 |